Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2019			10,000	10,529,000
Beginning Balance at Dec. 31, 2019	$ 20,553	$ 20,816	$ 0	$ 11	$ 438,911	$ 2	$ (417,400)	$ (708)	$ (263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,141)	(8,150)					(8,150)		9
Unrealized loss on marketable securities	(15)	(15)				(15)
Share-based compensation (in shares)				53,000
Share-based compensation	1,117	1,117		$ 0	1,117
Net proceeds from issuance of common stock (in shares)				8,807,000
Net proceeds from issuance of common stock and warrants	18,728	18,728		$ 8	18,720
Ending Balance (in shares) at Dec. 31, 2020			10,000	19,389,000
Ending Balance at Dec. 31, 2020	32,242	32,496	$ 0	$ 19	458,748	(13)	(425,550)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(27,466)	(27,466)					(27,466)		0
Unrealized loss on marketable securities	(57)	(57)				(57)
Share-based compensation (in shares)				517,000
Share-based compensation	1,757	1,757		$ 0	1,757
Net proceeds from issuance of common stock (in shares)				39,888,000
Net proceeds from issuance of common stock and warrants	$ 85,500	85,500		$ 41	85,459
Proceeds from option exercises (in shares)	7,250			7,000
Proceeds from option exercises	$ 24	24		$ 0	24
Ending Balance (in shares) at Dec. 31, 2021			10,000	59,801,000
Ending Balance at Dec. 31, 2021	$ 92,000	$ 92,254	$ 0	$ 60	$ 545,988	$ (70)	$ (453,016)	$ (708)	$ (254)